Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD
PMATAVP
1 other identifier
observational
30
1 country
1
Brief Summary
The goal of this exploratory, mixed-method design study is to gather qualitative and quantitative data obtained through interviews and questionnaires with veterans who are currently enrolled at the VA for healthcare. The main question this study aims to answer is: How do veterans diagnosed with PTSD and enrolled for care at the VA understand MDMA-assisted therapy for PTSD? Using a story-completion approach, participants will be provided with a brief story starter involving a fictitious character and scenario and asking them to complete the story. Few contextual details will be offered about the character. In responding to ambiguous cues, participants are thought to project their conscious and subconscious perceptions about the phenomenon in question onto the story, a useful method for exploring stigmatized topics. The purpose of this exercise is to ascertain the participants attitudes and perceptions regarding MDMA-Assisted Therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 8, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 23, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 23, 2023
CompletedFirst Submitted
Initial submission to the registry
May 31, 2023
CompletedFirst Posted
Study publicly available on registry
June 8, 2023
CompletedJune 22, 2023
June 1, 2023
8 months
May 31, 2023
June 20, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Patient Health Questionnaire 9
Screening tool for depressive symptoms. Scores range from 0-27 with lower scores indicating better outcomes
2 weeks
PTSD Checklist for DSM5
Screening tool for PTSD symptoms. Scores range from 0-80 with lower scores indicating better outcomes
4 weeks
5 Item Screener for PTSD
Screening tool for PTSD symptoms. Scores range from 0-4 with lower scores indicating better outcomes.
2 weeks
Eligibility Criteria
The demographic makeup of the sample mimics the demographic makeup of the population of veterans served by VA. As such, the racial distributions will likely be primarily Caucasian, the sample is likely to be predominantly male, ranging in age from 20-100, with an average of 58 years.
You may qualify if:
- Veterans enrolled in VA care
- Active diagnosis of PTSD, as determined by the referring provider or confirmed by medical records.
- Age 18 or older
- Fluent in written and spoken English
You may not qualify if:
- Cognitively impaired to the extent that patient cannot comprehend the survey
- Has already completed the interview
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stratton VA Medical Center
Albany, New York, 12208, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Caitlin Holley, Ph.D.
Stratton VA Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 31, 2023
First Posted
June 8, 2023
Study Start
August 8, 2022
Primary Completion
March 23, 2023
Study Completion
March 23, 2023
Last Updated
June 22, 2023
Record last verified: 2023-06